ORIGINAL RESEARCH article
Front. Immunol.
Sec. Vaccines and Molecular Therapeutics
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1604677
This article is part of the Research TopicAnimal-borne viral disease: Pathogenesis, Innate immunity, Acquired immunity, and Novel vaccine developmentView all 13 articles
Circular mRNA-LNP vaccine encoding self-assembled E2-TMD-mi3 nanoparticles licit enhanced CSFV-specific immunity over commercial subunit vaccine
Provisionally accepted- 1Shanghai Normal University, Shanghai, Shanghai Municipality, China
- 2National University of Singapore Suzhou Research Institute (NUSRI), Suzhou, Jiangsu Province, China
- 3Nanjing Agricultural University, Nanjing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The E2 subunit vaccine is crucial for eliminating Classical Swine Fever Virus (CSFV) due to its favorable biosafety and Differentiating Infected from Vaccinated Animals (DIVA) capability. However, low immunogenicity and high costs limit its broader application. To overcome these bottlenecks, we leveraged mRNA-LNP technology to design next-generation E2 glycoprotein vaccines with enhanced immunogenicity and cost-effectiveness. We designed different E2 glycoprotein coding sequences incorporating CD154 adjuvants and mi3 self-assembled nanoparticles, delivered via cmRNA-LNP formulations in murine immunogenicity testing. Among these, E2-TMD-mi3 cmRNA-LNP vaccine induced high-titer antibodies with a 78.25%±1.32% blocking rate at day 14 post-booster, significantly higher than the commercial subunit vaccine (39.74%±3.30%, p<0.01). To further optimize vaccine performance, we compared cmRNA-LNP formulations incorporating with different cationic lipids. Notably, AX4-LNP formulation induced superior cellular and humoral immunity compared to other cationic lipids. In mice, this vaccine induced robust humoral immunity, achieving a mean blocking rate of 80.55%±2.06% by day 14 post-booster, alongside potent cellular immunity (IFN-γ ELISpot, 319.60±45.23 SFC/10 5 cell, 5.6-fold higher than that of the commercial vaccine). In swine, the CSFV-specific antibody blocking rate remained at 54.76%±3.21% at 120 days post-primary vaccination. In contrast, the antibody blocking rates in other cmRNA-LNP vaccine groups and the commercial vaccine group were below the positivity threshold (<40%, set according to the manufacturer's technical specifications), outperforming commercial subunit vaccines. Moreover, this vaccine does not affect the body weight gain of immunized pigs and does not cause inflammatory reactions at the immunization site. Ultimately, we successfully developed a cmRNA-LNP vaccine incorporating the E2-TMD-Mi3 coding sequence and AX4-LNP, which demonstrated superior immunogenicity compared to commercial subunit vaccines. This study establishes a modular cmRNA- LNP platform combining mi3 nanoparticles, overcoming traditional subunit vaccine limitations for porcine viral pathogens.
Keywords: Classical swine fever virus, E2 glycoprotein, mi3 self-assembled nanoparticles, AX4-LNP, cmRNA-LNP vaccine
Received: 03 Apr 2025; Accepted: 03 Jun 2025.
Copyright: © 2025 Liu, Zhai, Diao and Yin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Feifei Diao, Nanjing Agricultural University, Nanjing, China
Bo Yin, National University of Singapore Suzhou Research Institute (NUSRI), Suzhou, Jiangsu Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.